TickerFacts.

Accustem Sciences Inc. (ACUT): Shareholders' Equity

Annual figures by period end, from SEC filings.

-$3.40M
As of 2025-12-31
-$4.12M
As of 2026-06-30
$650.7K2021-12-31: $650.7K2022-12-31: -$139.6K2023-12-31: -$2.11M2024-12-31: -$3.31M2025-12-31: -$3.40M-$3.40M
2021-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31-$3.40Mn/m2026-04-14, Balance as of period end
2024-12-31-$3.31Mn/m2026-04-14, Balance as of period end
2023-12-31-$2.11Mn/m2025-04-03, Balance as of period end
2022-12-31-$139.6Kn/m2024-03-22, Balance as of period end
2021-12-31$650.7Kn/a2023-02-15, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Accustem Sciences Inc. (ACUT)2025-12-31-$3.40Mn/m
Semnur Pharmaceuticals, Inc. (SMNR)2025-12-31-$20.75Mn/m
Aspire-Lakewood Holdings, Inc. (ASBP)2025-12-31-$6.38Mn/m
Alzamend Neuro, Inc. (ALZN)2026-04-30$733.2K-81.5%
NeuroSense Therapeutics Ltd. (NRSN)2025-12-31-$1.56Mn/m
Inhibitor Therapeutics, Inc. (INTI)2025-12-31-$1.29Mn/m
Vaccinex, Inc. (VCNX)2024-12-31-$2.49Mn/m
Ocean Biomedical, Inc. (OCEA)2024-12-31-$97.62Mn/a
Lipella Pharmaceuticals Inc. (LIPO)2024-12-31$1.92M-39.0%

Compare ACUT, SMNR, ASBP, ALZN side by side · Screen every company in Pharmaceutical Preparations ↗